Journal
AGING-US
Volume 12, Issue 3, Pages 2939-2951Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/aging.102788
Keywords
atorvastatin; subarachnoid hemorrhage; CVS; RCT
Categories
Funding
- Wuxi Key Disciplines Fund Major Project [ZDXK005]
- Nanjing Military Area Research Fund Major Project [15DX003]
- Wuxi Foundation for the Development of Science and Technology [WX18IIAN041]
Ask authors/readers for more resources
We explored whether acute atorvastatin treatment would improve clinical outcomes and reduce the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage in elderly Chinese adults. Patients (60 to 90 years old) were admitted to intensive care units after surgery to clip or embolize their aneurysms. We assessed 592 patients and assigned 159 to receive atorvastatin (20 mg/day) and 158 to receive placebo once daily for up to 14 days. The primary outcome was the Glasgow outcome scale at 6 months, and secondary outcomes were cerebral vasospasm, 30-days all-cause mortality, cerebral infarction, and delayed ischemic neurological deficit. The incidence of postoperative cerebral vasospasm (39.3% vs 56%, P=0.004) and cerebral infarction (18.7% vs 27.3%, P=0.027) were significantly lower in the atorvastatin group. The study did not detect benefits in the use of atorvastatin for 6 months clinical outcome or 30-day all-cause mortality, but it suggests that atorvastatin together with nimodipine can reduce cerebral vasospasm and cerebral infarction after subarachnoid hemorrhage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available